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330with stable CAD versus those
who experience plaque rupture
(1). Thus, signaling pathways
predisposing to atherosclerosis
probably differ from those con-
tributing to plaque vulnerability.
This distinction is likely to be
crucial when considering strate-
gies for identifying patients at
risk of MI and death from plaque
rupture.
The Framingham Risk Score
and similar scores are widely used
to assess absolute risk of adverse
cardiac events in patients without
known CAD (2,3); however, they
do not reliably predict risk of
plaque rupture (and consequent
MI and/or death) in patients with
already established CAD (4,5).
Other biomarkers appear to pre-
dict such risk, but their associated
hazard ratios (HRs) have beenmodest (6–8). Our purpose is to develop a robust, noninva-
sive, and simple biomarker strategy to identify CAD patients
at increased risk of plaque rupture.
The strategy we explored derived from the concept that
activation of multiple pathways, including inﬂammatory,
stress-related, and coagulation pathways, each contribute to
coronary plaque instability. Elevated levels of high-sensitivity
C-reactive protein (CRP) reﬂect vascular inﬂammation
and are associated with greater risk for subsequent cardio-
vascular disease (CVD) events, but the effects are modest
(9,10). Heat shock proteins (HSPs), including HSP70, are
highly conserved intracellular proteins that increase in
response to stress, and may provide evidence of increased
cellular stress, and thus, a predisposition to plaque rupture
(11–13). Both ﬁbrinogen and ﬁbrin degradation products
(FDP), end products in the coagulation cascade, have been
associated with CAD development and severity (14,15).
Moreover, D-dimer, a degradation product of ﬁbrinogen and
soluble ﬁbrin monomers, has been associated with adverse
cardiac events (16,17). We hypothesized that risk assess-
ment would be markedly enhanced when the 3 biomarkersd
CRP reﬂecting inﬂammation; HSP70, associated with in-
creased cellular stress; and FDP, associated with coagulation
cascade activationdare used in aggregate, that is, the risk of
plaque rupture would be greater when biomarkers reﬂected
activation of 2 or 3 pathways compared with activation of
0 or 1 pathways.Methods
Study population. Study participants were recruited as part
of the Emory Cardiology Biobank (EMCAB), consisting of
3,763 consecutive patients enrolled before undergoing electiveor emergent coronary angiograms across 3 Emory healthcare
sites, between2003 and2009 (details in theOnlineAppendix).
Outcomes and follow-up. Record of death was obtained
from the Social Security Death Index, and the cause of death
adjudicated from medical records or direct contact was made
with the patient’s family member(s). Cardiac death was
deﬁned as death attributable to a cardiovascular cause or
sudden death due to an unknown cause. Follow-up was
conducted between 1 and 5 years to identify cases of MI
and revascularization (deﬁned as percutaneous coronary
interventions or coronary artery bypass graft [CABG]
surgery). MI and revascularization occurring within a month
of enrollment were not included.
Identiﬁcation of CAD and severity scoring. All coronary
angiograms were scored for luminal narrowing using a modi-
ﬁed American Heart Association/American College of
Cardiology classiﬁcation of the coronaries (18). Patients were
designated as having either angiographically smooth normal
coronary arteries, nonsigniﬁcantCAD(visible plaque resulting
in <50% luminal stenosis), or signiﬁcant CAD (at least 1
major epicardial vessel with 50% stenosis). Quantitative
angiographic scoring was performed using the Gensini score,
whichquantiﬁesCADseverity by a nonlinear points system for
degree of luminal narrowing. The score has prognostic
signiﬁcance (19).
Sample collection. Fasting arterial blood samples for
serum were drawn at cardiac catheterization and stored
at 80C (mean 4.9 years) before analysis by FirstMark,
Inc. (San Diego, California) (Online Appendix). CRP and
FDP levels were determined using a sandwich immunoassay.
FDP components included fragments D and E, D-dimer,
and additional intermediate cleavage products. HSP70 was
measured with a sandwich enzyme-linked immunosorbent
assay (R&D Systems, Minneapolis, Minnesota) and opti-
mized by FirstMark. Minimum detectable CRP, FDP, and
HSP70 concentrations were 0.1 mg/l, 0.06 mg/ml, and
0.625 ng/ml, respectively.
Statistical analyses. Continuous variables are presented as
mean  SD, and categorical variables are presented as
proportions (percentages). Student t test, 1-way analysis of
variance, and Cochran-Mantel-Haenszel chi-square test
were used as appropriate. Mann-Whitney U or Kruskall-
Wallis nonparametric tests were performed on non-
normally distributed variables. The relationship between
biomarkers and outcomes was determined using the Cox
proportional hazards regression in unadjusted models and in
models adjusted for established risk factors that included
clinically relevant covariates for CVD outcomes (age at
baseline, race, diagnosis of hypertension, diabetes, dyslipi-
demia, use of statins, aspirin, clopidogrel, history of MI,
acute MI at presentation, estimated glomerular ﬁltration rate
[eGFR; calculated using the Modiﬁcation of Diet in Renal
Disease equation], Gensini score, body mass index, left
ventricular ejection fraction [LVEF], history of CABG, and
smoking status). The proportional hazards assumption for
Cox models was evaluated by plots of Schoenfeld residuals
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Schoenfeld residuals). No signiﬁcant violations of the
assumption were found.
Biomarkers were evaluated both as continuous (natural
log transformed) per SD (Online Fig. 1) and as categorical
variables based on cutpoints. Penalized B-splines within the
Cox models were also used to assess the functional form of
the association between each biomarker and events (20).
We also took into consideration clinically relevant cutpoints
(21). Through these evaluations, cutpoints were determined
as 3 mg/l for CRP, 1.0 mg/ml for FDP, and 0.625 ng/ml
for HSP70. The FDP cutpoint corresponded to the fourth
quartile. Analyses were performed on all participants, and
in subsets of those with and those without signiﬁcant
CAD.Table 1 Baseline Demographics, Clinical Characteristics, and Bioma
Characteristics
Entire Cohort 0
(n ¼ 3,415) (n ¼ 1,248)
Age (yrs) 63  11 64  11
Male 65 71
Caucasian 82 87
BMI (kg/m2) 30  6 29  6
Systolic BP (mm Hg) 137  23 137  22
Diastolic BP (mm Hg) 76  12 76  12
LDL (mg/dl) 99  38 96  35
HDL (mg/dl) 42  13 42  13
Glucose (mg/dl) 122  45 116  35
Catheterization: visually normal 9 11
Catheterization: >50% stenosis 67 67
Catheterization: Gensini score 39  59 41  61
LVEF 53  13 55  11
eGFR (ml/min) 77  47 78  43
History of DM 33 26
History of HTN 92 89
History of dyslipidemia 70 73
Ever smoked 59 56
AMI on presentation 12 7
History of previous MI 31 29
On statin 72 75
On ARB or ACE-I 62 59
On aspirin 81 81
On clopidogrel 46 45
On beta-blocker 63 58
CRP (mg/l) 7.2  13 1.3  0.8
HSP70 (ng/ml) 82  513 0.0  0.0
FDP (mg/ml) 3.7  16 0.5  0.2
Management: medical 57.4 58.8
Management: revascularization 40.9 39.4
Management: other 1.7 1.8
Follow-up: MI 3.6 1.6
Follow-up: revascularization 10.8 7.2
Follow-up: all-cause death 8.3 3.1
Values are mean  SD or %.
ACE-I ¼ angiotensin-converting enzyme inhibitor; AMI ¼ acute myocardial infarction; ARB ¼ angiote
DM ¼ diabetes mellitus; eGFR ¼ estimated glomerular ﬁltration rate; HDL ¼ high-density lipoprotein;
ventricular ejection fraction.The ability of the standard clinical model for predicting
adverse events was calculated using the C statistic from Cox
regression models before and after addition of the indepen-
dently predictive biomarkers identiﬁed both individually and in
aggregate (22). Using multivariate Cox models with the previ-
ously noted clinical covariates, continuous net reclassiﬁcation
improvement (NRI) and integrated discrimination improve-
ment (IDI) metrics were calculated. Values of p< 0.05 from 2-
sided tests were considered to indicate statistical signiﬁcance.
Further statistical methods are in the Online Appendix.
Results
Baseline characteristics of the 3,415 patients (age 63 
11 years) are shown in Table 1.rker Measurements
No. of Positive Biomarkers
p Value
1 2 3
(n ¼ 1,475) (n ¼ 565) (n ¼ 127)
62  13 65  12 65  11 <0.0001
61 62 60 <0.0001
81 80 74 <0.0001
30  7 30  7 28  6 <0.0001
138  23 137  25 135  24 0.343
76  12 76  12 74  13 0.350
102  39 100  39 98  35 0.001
42  13 40  12 42  15 0.016
124  46 131  56 126  57 <0.0001
10 6 6 0.001
65 72 64 0.240
35  53 47  66 44  61 0.001
54  13 51  13 47  18 <0.0001
81  50 69  48 61  47 <0.0001
35 39 45 <0.0001
93 92 93 0.019
70 68 54 <0.0001
60 61 67 0.002
15 17 2 <0.0001
30 37 30 0.024
72 72 61 0.005
66 60 60 0.248
81 84 72 0.424
45 53 45 0.048
65 67 72 <0.0001
8  12 15  20 18  24 <0.0001
30  140 224  829 839  1714 <0.0001
2.4  12 8.9  25 26  42 <0.0001
56.7 55.6 61.2 0.444
41.4 43.2 38.8 0.271
1.9 1.3 0 0.203
3.9 6.4 5.9 <0.0001
11.7 15.4 13.4 <0.0001
6.4 18.4 34.6 <0.0001
nsin-receptor blocker; BMI ¼ body mass index; BP ¼ blood pressure; CRP ¼ C-reactive protein;
HSP70 ¼ heat shock protein 70; HTN ¼ hypertension; LDL ¼ low-density lipoprotein; LVEF ¼ left
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332Relationship between biomarkers and prevalent CAD.
Compared with patients with angiographically normal
(smooth) coronary arteries, those with angiographic ath-
erosclerosis had higher levels of HSP70, but FDP and CRP
levels were not signiﬁcantly different. FDP and HSP70, but
not CRP levels, were signiﬁcantly lower in patients with
nonsigniﬁcant versus signiﬁcant CAD (Online Table 1A).
In univariate analysis, the Gensini CAD severity score was
signiﬁcantly higher in patients with elevated HSP70 and
FDP levels (above their respective cutpoints), but not in those
with an elevated CRP level (Online Tables 1B and 1C).
However, none of these differences remained signiﬁcant
after multivariate adjustment with the aforementioned co-
variates (Online Table 2).
Clinical and demographic predictors of adverse out-
comes. Over a median follow-up of 2.3 years, 283 patients
died (8.3%) (150 were cardiac deaths [4.9%] and 122 had an
MI [3.6%]), and 371 had revascularization (10.8%) (Table 1).
Using Cox proportional hazard models that included all the
aforementioned covariates, age (HR: 1.02, p ¼ 0.004),
diabetes (HR: 1.65, p < 0.0001), ever smoking (HR: 1.38,
p ¼ 0.0046), Gensini score (HR: 1.003, p ¼ 0.006), aspirin
use (HR: 0.62, p ¼ 0.001), clopidogrel use (HR: 1.51,
p¼ 0.0008), acuteMI at presentation (HR: 1.69, p< 0.0001),
eGFR (HR: 0.99, p < 0.0001), and LVEF (HR: 0.98,
p < 0.0001) were all independent predictors of the combined
outcomes of all-cause death and MI.
Relationships between individual biomarkers and out-
comes. Cox proportional hazard regression models,
adjusted for aforementioned covariates, performed for indi-
vidual biomarkers (natural log transformed) demonstrated
that HSP70 (HR: 1.14, p < 0.0001) and CRP (HR: 1.29,
p < 0.0001), but not FDP (p ¼ 0.90), were signiﬁcantly
associated with combined outcomes of death and MI.
However, elevated levels (above cutpoints) of HSP70, FDP,
and CRP were each associated with increased risk of all-cause
death, cardiac deaths, the combined endpoint of cardiac or
all-cause death andMI, and the combined endpoint of death,
MI, and revascularization (Table 2). All 3 biomarkers pre-
dicted adverse CVD events in subgroups with nonsigniﬁcant
CAD (<50% stenosis, n ¼ 1,480) and in those with
signiﬁcant CAD (50% stenosis, n ¼ 1,935) (Table 2).
Relationship between aggregate biomarker score and
outcomes. There were signiﬁcant but weak correlations
between CRP and both HSP70 and FDP, and between
HSP70 and FDP (Online Table 1B). For each patient,
a score of 0 or 1 was assigned based on the presence or
absence of elevated levels (above each cutpoint value) of
each of the 3 biomarkers, and an aggregate risk score
between 0 and 3 was calculated. Compared with those with
0 positive biomarkers (n ¼ 1,248), patients with an
elevated biomarker score were more often black, had lower
eGFRs and LVEFs, and had a greater frequency of dia-
betes and smoking history (Table 1). Among the 4 groups
stratiﬁed by biomarker positivity, there were no signiﬁcant
differences between the management strategy (medicalmanagement or revascularization) after index catheteriza-
tion (Table 1).
In unadjusted analyses, an increasing biomarker score (0
to 3) was associated with increased risk of all-cause death (p
for trend <0.0001), cardiac deaths (p for trend < 0.0001),
MI (p for trend <0.0001), and revascularization (p for
trend <0.0001) (Table 1). There was a stepwise decline in
survival free of death (log rank p < 0.0001), death and MI
events (log rank p < 0.0001), and the combined endpoint of
death, MI, and revascularization (log rank p < 0.0001) with
increasing biomarker risk score (Fig. 1).
The Cox proportional hazard regression model adjusting
for all the previously described covariates revealed that for
each 1 point increase in risk score, the HR increased 1.87
(p< 0.0001) for all-cause death, 1.79 (p< 0.0001) for cardiac
death, 1.76 (p< 0.0001) for combined outcomes of death and
MI, and 1.49 (p < 0.0001) for death, MI, and revasculariza-
tion.HRs of 1, 2, or 3 positive biomarkers comparedwith 0 are
shown in Table 2 and Online Table 3, and the rates of annual
CVD events in these aggregate risk score categories are shown
in Figure 2. The score was also associated with individual
events of MI (HR: 1.40, p ¼ 0.0024) and revascularization
(HR: 1.26, p¼ 0.0003) for each 1 point increase in risk score.
Discrimination testing. In the whole cohort and in the
patients with nonsigniﬁcant and with signiﬁcant CAD, the
C statistic increased signiﬁcantly for prediction of cardiac
deaths (referent C statistic ¼ 0.76, with added biomarker
score, 0.80; p ¼ 0.0002), all-cause death, for combined
events of death and MI, and for death, MI, and revascu-
larization, when all 3 biomarkers were incorporated into
a model with the established risk factors both as a risk score
or as categorical variables (Table 3).
The NRI of the biomarker score for all-cause death and
the combined events of death and MI were 44% and 42%,
respectively (Table 4). This corresponded to 14% and 13%
rates of correctly reclassifying events and 30% and 29% rates
of correctly reclassifying nonevents, respectively. The relative
IDI for this model was 31% for deaths and 30% for death
and MI. There was improvement in both subgroups with
and without signiﬁcant CAD, with a trend to greater NRI in
those without signiﬁcant CAD.
Subgroup analyses. Results were similar in the subgroups
with either signiﬁcant or nonsigniﬁcant CAD, including those
with normal coronary arteries (Table 2). A score of 3 corre-
sponded to an 18%/year risk of death andMI in the signiﬁcant
CAD group and a 14%/year risk in the nonsigniﬁcant CAD
group (Fig. 2). Even after excluding patients with angio-
graphically normal smooth coronary arteries and those with
acute MI on presentation, our results remained unchanged.
We examined whether there was heterogeneity in the HRs
based on age, sex, race, and presence of individual risk factors,
presentation with acute MI, severity of CAD, and eGFR
values. We found that aside from age (p ¼ 0.003), eGFR
(p¼ 0.03), and a diagnosis of hypertension (p¼ 0.009), there
was no signiﬁcant interaction (p > 0.05) among these factors
and the predictive capacity of the risk score (Fig. 3).
Table 2
Hazard Ratios for All-Cause Death, Combined Endpoints of Death and MI, and Combined Endpoints of Death, MI, and
Revascularization According to Biomarker Levels
Variables
All Participants Signiﬁcant CAD Nonsigniﬁcant CAD
HR (95% CI); p Value HR (95% CI); p Value HR (95% CI); p Value
All-Cause Death
All biomarkers in same model
CRP 3.0 mg/l 1.80 (1.36–2.38); <0.0001 1.60 (1.13–2.27); 0.0087 2.36 (1.46–3.81); 0.0005
HSP70 at 0.625 ng/ml 2.02 (1.51–2.70); <0.0001 1.86 (1.28–2.70); 0.0012 2.29 (1.42–3.69); 0.0007
FDP 1.0 mg/ml 1.91 (1.46–2.49); <0.0001 1.60 (1.13–2.27); 0.0087 1.74 (1.11–2.71); 0.0152
Continuous biomarker risk score 1.87 (1.63–2.15); <0.0001 1.74 (1.45–2.08); <0.0001 2.07 (1.65–2.60); <0.0001
Categorical biomarker risk score
1 vs. 0 markers 1.70 (1.16–2.50); 0.0065 1.76 (1.09–2.84); 0.0198 1.62 (0.84–3.13); 0.1520
2 vs. 0 markers 3.69 (2.52–5.41); <0.0001 3.26 (2.01–5.27); <0.0001 4.58 (2.39–8.80); <0.0001
3 vs. 0 markers 5.79 (3.63–9.22); <0.0001 4.89 (2.64–9.06); <0.0001 7.07 (3.33–15.03); <0.0001
Cardiac Death
All biomarkers in same model
CRP 3.0 mg/l 1.76 (1.19–2.60); 0.0049 1.59 (0.98–2.56); 0.0587 2.37 (1.17–4.81); 0.0164
HSP70 0.625 ng/ml 1.69 (1.13–2.53); 0.0102 1.46 (0.88–2.41); 0.1436 2.17 (1.07–4.40); 0.0327
FDP 1.0 mg/ml 2.00 (1.38–2.89); 0.0003 2.06 (1.29–3.27); 0.0023 1.69 (0.89–3.21); 0.1072
Continuous biomarker risk score 1.79 (1.47–2.17); <0.0001 1.68 (1.32–2.14); <0.0001 1.97 (1.41–2.75); <0.0001
Categorical biomarker risk score
1 vs. 0 markers 1.53 (0.90–2.58); 0.1155 1.54 (0.80–2.97); 0.1939 1.58 (0.64–3.90); 0.3255
2 vs. 0 markers 3.02 (1.77–5.15); <0.0001 2.94 (1.52–5.66); 0.0013 3.18 (1.24–8.17); 0.0163
3 vs. 0 markers 5.24 (2.79–9.86); <0.0001 4.26 (1.88–9.66); 0.0005 7.36 (2.56–21.17); 0.0002
All-Cause Death or MI
All biomarkers in same model
CRP 3.0 mg/l 1.61 (1.28–2.03); <0.0001 1.55 (1.17–2.06); 0.0023 1.93 (1.27–2.93); 0.0019
HSP70 0.625 ng/ml 2.26 (1.77–2.90); <0.0001 2.32 (1.70–3.15); <0.0001 2.18 (1.42–3.33); 0.0003
FDP 1.0 mg/ml 1.62 (1.28–2.04); <0.0001 1.50 (1.12–2.00); 0.0067 1.77 (1.18–2.66); 0.0059
Continuous biomarker risk score 1.76 (1.56–1.98); <0.0001 1.70 (1.46–1.97); <0.0001 1.92 (1.57–2.36); <0.0001
Categorical biomarker risk score
1 vs. 0 markers 1.83 (1.33–2.51); 0.0002 2.03 (1.38–2.99); 0.0003 1.50 (0.86–2.61); 0.15
2 vs. 0 markers 3.46 (2.51–4.78); <0.0001 3.31 (2.22–4.92); <0.0001 3.93 (2.25–6.87); <0.0001
3 vs. 0 markers 4.99 (3.31–7.53); <0.0001 4.80 (2.81–8.21); <0.0001 5.62 (2.86–11.06); <0.0001
All-Cause Death, MI, or Revascularization
All biomarkers in same model
CRP 3.0 mg/l 1.26 (1.06–1.49); 0.0084 1.13 (0.93–1.38); 0.22 1.86 (1.32–2.60); 0.0003
HSP70 0.625 ng/ml 1.97 (1.64–2.36); <0.0001 2.01 (1.62–2.50); <0.0001 1.95 (1.37–2.78); 0.0002
FDP 1.0 mg/ml 1.47 (1.22–1.76); <0.0001 1.32 (1.05–1.65); 0.0172 1.76 (1.26–2.46); 0.0010
Continuous biomarker risk score 1.49 (1.36–1.63); <0.0001 1.39 (1.25–1.55); <0.0001 1.84 (1.55–2.18); <0.0001
Categorical biomarker risk score
1 vs. 0 markers 1.59 (1.29–1.97); <0.0001 1.60 (1.26–2.04); 0.0001 1.69 (1.10–2.59); 0.0177
2 vs. 0 markers 2.44 (1.94–3.06); <0.0001 2.11 (1.62–2.75); <0.0001 3.68 (2.33–5.79); <0.0001
3 vs. 0 markers 3.05 (2.19–4.23); <0.0001 2.48 (1.63–3.77); <0.0001 5.41 (3.04–9.63); <0.0001
Values are hazard ratios (HRs) and 95% conﬁdence intervals (CI).
Abbreviations as in Table 1.
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Multiple pathways contribute to the development of
atherosclerotic plaque instability and thereby increase the
likelihood that plaques will rupture or erode. We identiﬁed 3
circulating biomarkers (CRP, FDP, and HSP70) that are
involved in signaling pathways that likely inﬂuence plaque
instability (including inﬂammation, coagulation, and stress-
induced cellular responses) and examined the hypothesis
that each biomarker would predict risk, but the more
biomarkers that were abnormal, the greater the expected
risk. Our results support the validity of our underlyinghypothesis. Among patients who underwent coronary
angiography for suspected or established CAD, these 3
biomarkers were signiﬁcant and independent predictors of
risk of all-cause death, cardiac death, combined outcomes of
death and MI, and death, MI, and revascularization.
Importantly, an aggregate score based on the number of
biomarkers that were abnormal was a more powerful pre-
dictor of higher risk. In comparison to patients with a
0 biomarker score, those who had a risk score of 3 (<5% of
the population) experienced over a 5-fold increased risk
of all-cause death or MI within 1 year, with an annual rate
of more than 16%. The aggregate risk score signiﬁcantly
Figure 1 Kaplan-Meier Survival
Survival curves for biomarker risk score for (A) death and (B) death and
myocardial infarction (MI). Number of positive biomarkers are listed adjacent to
each survival curve.
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334improved discrimination of future death and MI risk over
a standard clinical model, as evidenced by improvement in
the C statistic and NRI.
Current evidence suggests that signaling pathways and
their effector molecules involved in the development of
plaque rupture are different from pathways involved in
atherogenesis. Thus, a biomarker that is a predictor of
adverse events emanating from the development of CAD in
a population that is initially free of existing CAD is not
necessarily a predictor of events in patients with established,
or likely, CAD.
C-reactive protein. Many population-based studies in
subjects free of known CAD have found that CRP adds to
risk prediction above standard risk factor assessment (23,24).
However, results remain unclear in patients with CAD. In
a meta-analysis of 83 studies in patients with CAD, an
elevated CRP posed an adjusted relative risk of only 1.19(25). In our high-risk population, an elevated CRP level
increased risk by a higher, but still modest, 1.6-fold.
Heat shock protein 70. Heat shock or stress proteins are
highly conserved molecules that fulﬁll a range of functions,
including cytoprotection and the intracellular assembly,
stabilization, folding, and translocation of oligomeric pro-
teins. Their synthesis can be induced by a range of cellular
insults, including oxidative, hemodynamic, and inﬂamma-
tory stress, all of which are associated with the development
of CAD (11–13). The relation between cardiovascular
outcomes and circulating HSP70 levels is controversial.
In cross-sectional studies, elevated levels of HSP70 were
associated with a lower prevalence of CAD and of carotid
intimal thickness (26,27). These differences are most likely
due to the fact that previous studies investigated risk of
atherogenesis, whereas our present investigation focuses on
whether the biomarkers are predictive of subsequent plaque
rupture. HSP70 levels increase after an acute MI, indicating
that acute MI can cause an increase in HSP70 (28,29). In
our study, 12% of patients presented with an acute MI;
however, our ﬁndings did not change after exclusion of
this subset.
Fibrin degradation products. We employed FDP, and not
D-dimer, to assess coagulation products. The immunoassay
was designed to detect the full complement of ﬁbrin and FDP
(ﬁbrin mono- and oligomers, fragments -X, -Y, and -E),
providing an increased ability to measure coagulation-related
products. Moreover, we found that FDP was not a predictor
of adverse events when used as a continuous variable, but
was an independent predictor using the cutoff value. This
suggests that there is threshold value for FDP (>75th
percentile of the population mean) above which it is asso-
ciated with increased risk, and not with a continuous addi-
tive risk with increasing values.
Previous studies have only examined the value of D-dimer
levels with respect to long-term outcomes. In population-
based studies, D-dimer levels predicted adverse cardiovas-
cular events, but was not always independent of CRP
(16,30). Importantly, in the BARI 2D (Bypass Angioplasty
Revascularization Investigation 2 Diabetes) study, the dia-
betics with CAD had higher D-dimer levels that were
associated with an increased risk of cardiac events (31).
Use of multiple biomarkers. Previous studies examining
the role of multiple biomarkers in populations free of
established CAD have demonstrated only slight improve-
ment in predictive capacity (using C statistic) when added to
standard clinical models (6–8). In contrast, our study
establishes the value of a multimarker aggregate score in a
population with suspected or established CAD, a group in
which conventional risk scores such as the Framingham Risk
Score have failed to identify risk of recurrent cardiac events.
The measured biomarkers were not associated with either
the presence or severity of CAD after adjustment for risk
factors, again emphasizing the concept that a biomarker that
reﬂects plaque instability is not necessarily useful for
Figure 2 Annual Rate of Death and MI
Rate of death and MI grouped by coronary artery disease (CAD) status and by biomarker score. Percent of patients within each group listed in individual bars. Abbreviation as in
Figure 1.
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335identifying presence or severity of coronary plaque. There
was minimal heterogeneity in the value of the biomarker risk
score based on clinical variables, risk factors, medication use,
and LVEF. Patients presenting with acute MI, which
constituted 12% of our cohort, also had similar risk
prediction compared with those without MI at presentation,
and exclusion of these patients did not signiﬁcantly alter risk
prediction. Approximately two-thirds of our CAD patients
underwent revascularization, and the remaining were treated
with medical therapy upon discharge after cardiac catheter-
ization; however, the rate of revascularization was similar
between the various biomarker risk score groups. Including
the revascularization strategy in the Cox regression model
did not alter the overall HRs for the biomarker risk score.
Clinical cardiac events that include death, MI, and
revascularization potentially result from complex kineticTable 3 C-Statistic for Cox Regression Models P
Variables
All Participants
C Statistic; p Value
All-cause death
Established risk factors 0.722; referent
Established risk factors þ score 0.784; <0.0001
All-cause death and MI
Established risk factors 0.694; referent
Established risk factors þ score 0.750; <0.0001
All-cause death, MI, and
Revascularization
Established risk factors 0.677; referent
Established risk factors þ score 0.707; <0.0001
Abbreviations as in Table 1.interactions between the magnitude of vascular stenoses and
factors that characterize plaque instability (32). The stenotic
severity, reﬂected by the Gensini score, drives symptoms and
some revascularization procedures, whereas plaque instability
leads to death and MI events. Our results are in agreement
with this concept because the Gensini score and the
biomarkers were all independent predictors of outcome.
Study strengths. We enrolled consecutive individuals,
including women (35% of total cohort), blacks, those with
acute MI, and patients with a range of LVEFs, reﬂecting
a population that is typical of those undergoing cardiac
catheterization. This is different from many biomarker
studies that are conducted retrospectively on highly select
populations enrolled in clinical trials. Assays were performed
at 2 time points by the same laboratory personnel, which
minimized variability. C statistics, NRI, and IDI wereredicting Major Adverse Cardiovascular Events
Signiﬁcant CAD Nonsigniﬁcant CAD
C Statistic; p Value C statistic; p Value
0.734; referent 0.755; referent
0.783; <0.0001 0.815; 0.001
0.703; referent 0.708; referent
0.744; <0.0001 0.773; 0.001
0.653; referent 0.691; referent
0.671; 0.009 0.751; 0.0006
Table 4 NRI and IDI for Death and MI Using Biomarker Score
Variables All Participants Signiﬁcant CAD Nonsigniﬁcant CAD
Events correctly
reclassiﬁed
13% 6% 16%
Nonevents correctly
reclassiﬁed
29% 26% 29%
NRI 42% 33% 45%
IDI 0.03 0.03 0.03
IDI ¼ integrated discrimination improvement; NRI ¼ net reclassiﬁcation improvement;
other abbreviation as in Table 1.
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336calculated using survival models that allowed for better
model discrimination and overall predictive ability.
Study limitations. Limitations of our study include a
1-time measurement of biomarkers that may not reﬂect
levels at future time points. We have not studied other
biomarkers, such as myeloperoxidase, or myocardial speciﬁc
markers, such as troponin and brain natriuretic peptide. Our
results need to be further validated and should not be
extrapolated to the general population without suspected or
known CAD. Whether more aggressive management inFigure 3
Forest Plot of Interaction With Cardiovascular Risk
Factors for 1 Unit of Biomarker Risk Score for
Outcomes of Death and MI
AMI ¼ acute myocardial infarction; eGFR ¼ estimated glomerular ﬁltration rate;
LVEF ¼ left ventricular ejection fraction.patients with an elevated biomarker risk score will modify
the score, and whether that will reﬂect lower risk remains
unknown and needs further investigation.
Although we characterized these biomarkers as repre-
sentatives of speciﬁc biologic pathways, signaling molecules
are often involved in multiple pathways that interact with
each other. For example, HSP70 pathways independent of
cellular stress may also contribute to its biological actions
(11–13,33). Our intent, therefore, was to use these 3
biomarkers as probable reﬂectors of activation of multiple
pathways commonly associated with vulnerable plaque.
Conclusions
We have demonstrated that a strategy using an aggregate
risk score consisting of 3 biomarkers (individually involved
in inﬂammation, coagulation, and stress-induced cellular
responses) identiﬁes patients with suspected or with estab-
lished CAD who are at increased risk of experiencing death
and other adverse cardiac outcomes in the near and medium
term. Whether treatment aimed at reducing activity of these
pathways can positively alter the disease course remains to be
determined and could be addressed in an adequately pow-
ered randomized interventional trial based on biomarker
evaluation.
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